

Highlights of This Issue 2251

SMALL MOLECULE THERAPEUTICS

- 2253** **The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation**
Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, and Sheng-Bin Peng
- 2264** **Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth**
Krishnendu Pal, Alexandre A. Pletnev, Shamit K. Dutta, Enfeng Wang, Ruizhi Zhao, Aradhita Baral, Vinod Kumar Yadav, Suruchi Aggarwal, Soundararajan Krishnaswamy, Khalid M. Alkharfy, Shantanu Chowdhury, Mark R. Spaller, and Debabrata Mukhopadhyay
- 2276** **Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor**
 Ziyang Y. Pessetto, Yan Ma, Jeff J. Hirst, Margaret von Mehren, Scott J. Weir, and Andrew K. Godwin
- 2288** **Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer**
Melissa A. Babcook, Sanjeev Shukla, Pingfu Fu, Edwin J. Vazquez, Michelle A. Puchowicz, Joseph P. Molter, Christine Z. Oak, Gregory T. MacLennan, Chris A. Flask, Daniel J. Lindner, Yvonne Parker, Firouz Daneshgari, and Sanjay Gupta
- 2303** **The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth**
Michael D. Arensman, Donatello Telesca, Anna R. Lay, Kathleen M. Kershaw, Nanping Wu, Timothy R. Donahue, and David W. Dawson
- 2315** **BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD**
Warren Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Santhana G.T. Devaraj, Christopher Leveque, Bryce P. Portier, Swaminathan Iyer, James E. Bradner, and Kapil N. Bhalla

- 2328** **Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma**
Raghavendra Gowda, SubbaRao V. Madhunapantula, Arati Sharma, Omer F. Kuzu, and Gavin P. Robertson


LARGE MOLECULE THERAPEUTICS

- 2341** **Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon- α**
Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang, and David M. Goldenberg
- 2352** **Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer**
Christopher L. Daige, Jason F. Wiggins, Leslie Priddy, Terri Nelligan-Davis, Jane Zhao, and David Brown

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 2361** **Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer**
Isabel R. Schlaepfer, Leah Rider, Lindsey Ulkus Rodrigues, Miguel A. Gijón, Colton T. Pac, Lina Romero, Adela Cimic, S. Joseph Sirintrapun, L. Michael Glodé, Robert H. Eckel, and Scott D. Cramer
- 2372** **Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1**
Carolina Castilla, M. Luz Flores, Rafael Medina, Begoña Pérez-Valderrama, Francisco Romero, María Tortolero, Miguel A. Japón, and Carmen Sáez
- 2384** **Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs**
Laurence Booth, Jane L. Roberts, Nichola Cruickshanks, Steven Grant, Andrew Poklepovic, and Paul Dent
- 2399** **Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells**
Jessian L. Munoz, Vivian Rodriguez-Cruz, Steven J. Greco, Vipul Nagula, Kathleen W. Scotto, and Pranela Rameshwar

Table of Contents

- 2412** **BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine**
 Rebecca M. Jones, Panagiotis Kotsantis, Grant S. Stewart, Petra Groth, and Eva Petermann
- 2422** **Piperlongumine Chemosensitizes Tumor Cells through Interaction with Cysteine 179 of I κ B α Kinase, Leading to Suppression of NF- κ B–Regulated Gene Products**
Jia Gang Han, Subash C. Gupta, Sahdeo Prasad, and Bharat B. Aggarwal
- 2436** **Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46**
Ute Jungwirth, Johannes Gojo, Theresa Tuder, Gernot Walko, Martin Holcman, Thomas Schöfl, Karin Nowikovsky, Nastasia Wilfinger, Sushilla Schoonhoven, Christian R. Kowol, Rosa Lemmens-Gruber, Petra Heffeter, Bernhard K. Keppler, and Walter Berger

MODELS AND TECHNOLOGIES


- 2450** **An *In Vivo* Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis**
Jonathan W. Astin, Stephen M.F. Jamieson, Tiffany C.Y. Eng, Maria V. Flores, June P. Misa, Annie Chien, Kathryn E. Crosier, and Philip S. Crosier
- 2463** **Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D**
Ningning He, Nayoung Kim, Mee Song, Choa Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyunga Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills, and Sukjoon Yoon

 AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Zebrafish embryos can be used to examine mechanisms of vascular development and as a platform with which to identify novel antivascular agents; this is an image of a 2-day-old zebrafish embryo showing developing lymphatic vessels in green (*lyve1:egfp*) and endothelial cell nuclei in red (*kdr1:nls:mcherry*). This embryo was live imaged for a further 20 hours to identify novel inhibitors of lymphatic vessel growth and revealed that flunarizine, a calcium channel antagonist, was able specifically induce lymphatic endothelial cell death. For details, see the article by Astin and colleagues on page 2450.



Molecular Cancer Therapeutics

13 (10)

Mol Cancer Ther 2014;13:2251-2473.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/13/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/13/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.